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THE DEVELOPMENT OF A PATIENT OUTCOMES
SOFTWARE FOR UROLOGISTS: CaPSURE POSTM
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Many urologists have limited resources to track and ana-
lyze the clinical and health-related quality of life out-
comes of prostate cancer patients. We developed software
that compiles clinical and quality of life data and pro-
vides benchmarking capabilities against a national data-
base of prostate cancer patients (CaPSURETM).
METHODS: We randomly surveyed 50 urologists with a
minimum of 5 years in practice, access to a computer in
their office, and under the age of 65 . To determine which
features of a software program would be most interesting
to them, urologists rank ordered eight areas of clinical
practice: demographics, clinical staging, imaging, treat-
ment, symptoms, medications, quality of life, and patient
satisfaction. A software prototype (CaPSURE POSTM)
was designed based on survey results and beta-tested with
urologists. Physicians enter data on prostate cancer pa-
tients prospectively at the time of office visits. Patients
record responses on a quality-of-life instrument. Individ-
ual and group practice data can be tabulated and bench-
marked against the national CaPSURETM database.
RESULTS: 80% of urologists stated they would likely
use the patient outcomes software in their practice. The
software features described as most useful included: clini-
cal staging, imaging, treatment, and quality of life. Major
software components include: PSA graphing, the Partin
Nomogram, treatment patterns by demographics/disease
stage, survival rates, resource use, and quality of life mea-
surements.
CONCLUSIONS: The ability of CaPSURE POSTM to an-
alyze treatment and quality of life outcomes may be of
significant value for urologists in a competitive health
care environment and to improve outcomes for patients
with prostate cancer.
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USE OF ADMINISTRATIVE DATABASES IN
SASKATCHEWAN, CANADA, FOR
PHARMACOECONOMIC AND
OUTCOMES RESEARCH
Downey W. Stang MR
Saskatchewan Health, Regina, Saskatchewan, Canada
Automated administrative databases are being used in-
creasingly in pharmacoeconomic and outcomes research
studies. These databases reflect actual payments for spe-
cific plans and populations, and analyses of objective in-
formation for drug exposure and health outcome studies
can be conducted cost-effectively.
OBJECTIVE: This is a descriptive paper on information
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available in population-based health services databases in
the Canadian Province of Saskatchewan.
DISCUSSION: In Saskatchewan, the provincial Depart-
ment of Health funds a number of universal health pro-
grams for the provincial population (currently about one
million people). As a result, the Department maintains
large computer databases that include more than 20 years
of data on outpatient prescription drug use and over 25
years of data on hospital separations, physician services,
and cancer cases for the provincial population. The data-
bases can be linked electronically by a health services
number unique for each individual. Specific cost and pay-
ment information is available for physician services and
prescription drug use. Prescription drug cost information
includes the drug material cost, mark-up, and profes-
sional fee components by individual brand dispensed as
well as by amount paid by patient and government, en-
abling pharmacoeconomic analyses from various perspec-
tives. Review of primary records (e.g., hospital charts)
and patient surveys can be conducted to obtain addi-
tional outcome data not available in the administrative
databases. Saskatchewan Health recognizes the value of
these data for outcomes and health services research and
has established procedures and guidelines to facilitate use
of the data for research while maintaining individual pri-
vacy and the integrity of the files. A number of pharrna-
coepidemiological and pharmacoeconomic studies have
been completed using the Saskatchewan data. This pre-
sentation will highlight the data available and the poten-
tial to contribute further to outcomes research.
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Allocation of limited health care resources is a problem
faced by decision makers. In an effort to ease this burden,
the idea has developed that economic efficiency can be
compared among interventions by the use of league ta-
bles-lists of interventions and their corresponding cost-
effectiveness ratios derived from various studies. League
tables simplify a huge amount of information into a few
numbers postulated to be critical to the decision. Desir-
able as it may be, this simplicity is not warranted. The
very concept is suspect as the ratios listed do not compare
the cited intervention to the one of interest. Even when all
compare to a common reference intervention, they repre-
sent inappropriate average ratios. Methodology and as-
sumptions made in creating the individual economic
models vary greatly but are typically ignored in the league
table. Even without the questionable methods used in
some analyses, real and important differences will always
exist among models (e.g., disease variation, purpose of
studies, and data availability). Even among studies con-
ducted by the same researchers, relevant differences arise.
For example, in one study on prevention of cardiovascu-
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lar disease the cost estimates included only initial acute
care. In another on stroke prevention, also by us, costs in-
cluded subsequent care for up to 15 years after the initial
event. This difference can substantially influence the re-
sulting cost-effectiveness ratios. Both approaches are cor-
rect for their purpose, but the difference would be un-
known to the decision maker viewing the league table.
League tables mislead decision makers into feeling in-
formed without realizing how little is known. These
problems cannot be cured by methodological guidelines.
Pharmacoeconomic researchers should resist creating
league tables and thereby providing both too little and
too much information to decision makers.
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APPLICATION OF PHARMACOECONOMICS
AND OUTCOMES RESEARCH IN FORMULARY
DECISION·MAKING
Sarpong OF
Xavier University, College of Pharmacy, New Orleans, LA. USA
The present reformed health care system is driven mainly
by cost containment. This poses some challenges to
health care practitioners in regard to the decision on
which therapeutic agents (drugs) get added or deleted
from the formulary. The challenge is in utilizing pharrna-
coeconomic tools and outcomes (clinical and humanistic)
research to arrive at a formulary that provides the patient
with effective drug therapy. The literature suggests that
effective drug therapy improves clinical outcomes and en-
hances patients' quality of life.
OBJECTIVES: The primary objective of this pilot study
was to assess the use or extent of use of pharmacoeco-
nomic methods and clinical and humanistic outcomes by
pharmacists (serving on a pharmacy and therapeutic
[P&T) committee) in making formulary decisions. The
secondary objective of the study was to examine the asso-
ciation between training in pharmacoeconomics and out-
comes research, and the application of the principles and
methods of these two disciplines.
METHODS: A 3D-item survey instrument was adminis-
tered to a convenient sample of 17 pharmacists. The in-
strument was designed to collect data on the demograph-
ics, pharmacoeconomics and outcomes research training,
and application of pharmacoeconomic tools and out-
comes research to formulary decision-making.
RESULTS: The percentage of respondents who indicated
using cost-minimization, cost-effectiveness, cost-benefit,
cost-utility, onset of action of drug/therapy, and recur-
rence of symptoms in formulary decision-making was
82.4%, 58.8%, 70.6%, 29.4%, 64%, and 76.5%, re-
spectively. There were a number significant correlations
between the application of pharmacoeconomic methods
and outcome measures (clinical and humanistic). Gener-
ally, there was no significant association between formal
training and application of the pharmacoeconomic meth-
ods and outcomes research.
CONCLUSION: The study suggests that pharmacists on
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P&T committees generally apply pharmacoeconomic
methods and outcomes research in making formulary de-
cisions.
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This paper outlines a decision model for evaluating the
effect of information regarding toxicity, efficacy, cost,
and alternative treatments on anticipated adoption rates
of developmental compounds.
METHODS: The paper discusses the relationship be-
tween multiattribute utility theory and people's prefer-
ences for health outcomes. Health outcomes arising from
pharmaceutical interventions are viewed as multiattribute
commodities. A method for reliable quantification of
health-state preferences is described. This procedure re-
quires estimating utility weights from stated-preference
(SP) data. By including health cost as an SP attribute,
marginal utilities are converted to marginal dollar values
to explicitly account for cost in determining market
share. Additionally, SP allows for a nonlinear association
between willingness to pay and health states reflecting the
diminishing marginal utility of health. Furthermore, this
technique permits estimating weights for combined
health states. A recent SP design for eliciting respondent
trade-offs among episode duration, symptom, daily-activ-
ity limitations, and cost is presented. Additionally, vari-
ous utility specifications and simplifying assumptions are
described. Finally, a rule for simulating aggregate choice
behavior is presented. The prediction rule employed
draws upon random utility theory. This method ad-
dresses the probabilistic nature of choices by including a
residual term to represent the effect of unobserved factors
on utility. A numerical example demonstrates the capa-
bility of the decision model. In this example, a general,
preference-based form for health-related utility facilitates
direct estimation of health attribute utility weights arising
from pharmaceutical product choice. This example dem-
onstrates how the model evaluates the impact of cost,
outcomes, and competition on anticipated drug adoption
rates.
CONCLUSION: Integrating stated-preference data, ran-
dom-utility modeling, and cost-utility analysis provides a
reliable way to describe preferences and predict choice
behavior. This capability provides important information
for developmental pharmaceutical product marketing
decisions.
